Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02454010 · ClinicalTrials.gov registry record · Phase 1

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

A Phase 1 study of Solid Tumor, sponsored by Fujifilm Pharmaceuticals U.S.A..

Completed
Registry status
Phase 1
Development phase
73
Enrollment target
4
Study locations

NCT02454010: Completed Phase 1 study of Solid Tumor, sponsored by Fujifilm Pharmaceuticals U.S.A..

NCT02454010 is a Phase 1 study of Solid Tumor that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 73 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02454010, a Phase 1 study of Solid Tumor, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..

COMPLETED
Registry status
Phase 1
Development phase
73 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.

Primary Outcome

measured by number of patients with adverse events leading to discontinuation or number of patients with dose limiting toxicity

Conditions Studied

Solid Tumor

Interventions

  • BIOLOGICAL FF21101

Study Locations (4)

Georgia

  • Winship Cancer Institute - Emory University - Atlanta

Illinois

  • Northwestern University - Feinberg School of Medicine - Chicago

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Texas

  • University of Texas M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2016-01
Est. Completion 2021-10
Phase Phase 1
Fujifilm Pharmaceuticals U.S.A.

8 total trials

What the finished NCT02454010 record still lists

NCT02454010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which FF21101 is the first listed.

NCT02454010 reports a single indexed study location in Georgia, Illinois, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT02454010 about?

NCT02454010 is a clinical study titled "A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer". The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.

What is the current status of trial NCT02454010?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2016-01. Estimated completion is 2021-10.

What conditions does trial NCT02454010 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT02454010?

The interventions under investigation include: FF21101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02454010?

This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02454010 being conducted?

This trial has 4 study locations across Georgia, Illinois, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02454010's enrollment target sits among peer trials

73 103rd of 196 higher than 94 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02454010, the US trial registry maintained by the National Library of Medicine. NCT02454010 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.